INTRODUCTION
Intraocular injection is a popular route for administration of gas, antibiotics, steroids, anti-vascular endothelial growth factor agents, and antiviral medications in many ocular conditions. 1, 2 Complications including endophthalmitis, uveitis, vitreous hemorrhage, cataracts, ocular hypertension and glaucoma, and retinal detachment have been reported after intraocular injections. 3 Although intraocular injection is a fast and simple procedure performed through a small wound, it has been shown that the presence of only a small number of bacteria is sufficient to induce endophthalmitis, the prevalence of which depends on the setting and indication for injection. This is of particular concern in penetrating eye injuries (PEIs) where it is a common assumption that dirty lacerations are more likely to become infected, possibly due to inability of the vitreous to clear microorganisms. The incidence of endophthalmitis following intravitreal injections unrelated to trauma or acute post-traumatic bacterial endophthalmitis (APBE) varies from 0.014 to 0.87% per injection and from 0.7 to 2.9% per eye. [4] [5] [6] [7] [8] [9] [10] Intraocular administration of antibiotics for prophylaxis against APBE has recently gained considerable attention. [11] [12] [13] This route of administration bypasses the blood-ocular barriers and appears to be the most effective method of achieving high drug concentrations inside the eye without systemic side effects. 6 However, intraocular injection in PEI may entail more complications as compared to routine injections because of technical issues such as visibility. [14] [15] [16] Some investigators believe that prophylactic intraocular medications should be used cautiously because there may be an additional risk of endophthalmitis, particularly following PEI. 13 The Traumatic Endophthalmitis Trial (TET) 17, 18 was a multicenter randomized controlled trial in which four major tertiary eye care centers randomized eligible patients with PEI to prophylactic intravitreal injection of clindamycin and gentamicin versus balanced salt solution (BSS) during primary repair. This study demonstrated a significantly lower rate of APBE in antibiotic injected eyes as compared to BSS injected eyes. However, there were Figure 1 . Schema of the current study population. The Traumatic Endophthalmitis Trial (TET) 17, 18 protocol required randomized patients to receive injection of intraocular antibiotics versus balanced salt solution (BSS) after primary repair (346 eyes). A total of 111 non-randomized patients (who declined intraocular injection after primary repair) with one month of follow-up served as controls. criticisms that intraocular BSS injection per se could have increased the risk of APBE in the control group. 15 We undertook this study to revisit the TET trial 17, 18 data and compare the rate of APBE in patients who received BSS (control arm of the trial) with that of eligible patients who had refused enrollment and received only standard care (systemic and topical antibiotics) without any intraocular injection (Fig. 1 ).
METHODS
The study followed the protocol of the TET trial 17, 18 and adhered to the tenets of the declaration of Helsinki. 19 It was approved by the Ethics Committee of the Ophthalmic Research Center and by the Iranian Research Center for Medical Sciences.
Patients
Patients referred for PEI to four major academic eye care centers in Iran over a 5-year period (July 1999 to September 2004) were reassessed. Data on patients randomized to the BSS injection arm (n=167) of the TET trial 17, 18 and eligible patients who had refused enrollment in the trial and had received only standard care (systemic and topical antibiotics) without intraocular injection during primary repair (n=111) were re-evaluated.
Exclusion criteria were absence of light perception, presence of endophthalmitis at the time of initial evaluation, total corneal opacity, age younger than 3 years, severe hyphema, history of intraocular surgery and presence of a corneal ulcer. Monocular patients and the better eye in bilateral injuries were also excluded.
Initial Management
A complete ocular examination was performed in all patients, details of which have previously been described. 17, 18 In brief, all eligible patients were admitted for primary repair and administration of intravenous gentamicin sulfate (3-5mg/kg) every 8 hours along with cefazolin sodium (50mg/kg) every 6 hours, for 5 days following surgery. In the original trial, enrolled case and control eyes with lacerations anterior to the rectus muscle insertions and an intact lens capsule received intracameral injection of gentamicin sulfate (40 micrograms) and clindamycin (45 micrograms) versus 0.1ml BSS, respectively. Eyes with lacerations limited to or extending posterior to the rectus muscle insertions or those with a ruptured lens capsule received the same injections through an intravitreal route.
For the purpose of the current study, data on a cohort of patients who were eligible for the TET trial but declined enrollment were analyzed. This group received all of the above mentioned standard treatments except for intraocular injection of any nature.
Surgical Technique
All patients underwent surgery under general anesthesia. Corneal and scleral lacerations were repaired in a standard fashion. In the BSS injection group, intracameral injections were performed through the limbus via a #27 needle. Intravitreal injections were performed through the sclera, 4mm posterior to the limbus in phakic eyes (3.5mm in aphakic eyes). 18 At the conclusion of surgery, 20 mg gentamicin and 4 mg betamethasone were injected subconjunctivally in all patients.
Postoperative Medications and Follow-up
The postoperative regimen included gentamicin drops four times a day and atropine drops three times a day for 1 week. Topical betamethasone was also administered four times a day for 6 weeks. Oral prednisolone (1mg/kg/ day) was initiated 24 hours postoperatively and tapered after approximately 1 week depending on the severity of inflammation.
All patients were hospitalized for 15 days and underwent daily examinations. One masked independent observer examined the patients on days 1, 2, 3, 5, 7 and 14. A complete ophthalmologic examination was performed during each visit to determine the amount of anterior chamber and vitreous reaction, and haziness. In eyes with poor visibility of the posterior segment, echography was performed 24 hours after primary repair to detect posterior segment complications. An orbital x-ray was obtained for all patients as well as a highresolution orbital computed tomographic scan for those suspected of a retained intraocular foreign body (IOFB).
Main Outcome Measures
The primary outcome measure was the development of APBE 2 weeks following primary repair. Endophthalmitis was diagnosed in the setting of pain, lid swelling, decreased visual acuity and 3+ or more cells in the anterior chamber together with any of the following signs: vitritis with loss of red reflex, vitreous involvement detected by echography in eyes with media opacity, or a positive culture of harvested intraocular fluids. The diagnosis of endophthalmitis was confirmed by two other masked independent observers. Secondary outcome measures included the rate and type of additional procedures required during hospitalization.
Statistical Analysis
For descriptive purposes, we described quantitative variables in mean ± standard deviation (SD) and qualitative variable in rates and percentages. For univariate analysis, the chi-square test and independent sample t-test were used. A logistic regression model was utilized to assess the simultaneous effect of treatment modality and presence of IOFB on the development of endophthalmitis. Data management and analysis was conducted by a masked statistician using SPSS software, version 15.0. P-values less than 0.05 were considered as statistically significant. Table 2 details additional surgical procedures in the study groups.
RESULTS

Characteristics and Initial Status of Patients
Post Hoc Power Analysis
The current study showed no significant difference between the study groups regarding APBE. The power of the study was 76.2% for detecting a 10% difference between the study groups and 53% for detecting a 7% difference. Post hoc power analysis revealed that with study power set at 80%, the required sample size for detection of a 10%, 7% and 0.3% intergroup difference (the actual value observed in the current study) would be 131, 232, and 77,242 eyes respectively. In other words if we consider the observed 0.3% intergroup difference in the rate of APBE to be clinically significant, a sample size of over 77,000 eyes would be required to demonstrate it with adequate statistical power.
DISCUSSION
The current study was performed to address criticisms on our previous multicenter randomized controlled trial 17,18 which compared intraocular antibiotics versus BSS injection and to determine the role of prophylactic intraocular antibiotic injection on the incidence of APBE. Table 2 . Additional surgical procedures in the study groups
The former study concluded that such injections have a protective role in the development of APBE. However, some opponents believed that the control group in the TET study may have developed a higher rate of infection causing an artifactual benefit in favor of the treatment group, or that we may have unnecessarily exposed our control group to risks of intraocular injection. 15 We revisited the available data on the control arm of the TET study (eyes receiving intraocular BSS) and data on patients who had been eligible for enrollment but declined to do so. These patients had received a standard treatment protocol of admission, intravenous antibiotics, primary repair, and subconjunctival antibiotics, followed by a 5-day period of intravenous antibiotics and addition of topical antibiotics. The latter group served as a new control group for the present study and were similar to the control arm of the TET study in all aspects except for lack of intraocular injections.
The incidence of APBE in patients who received intraocular injection of BSS and patients who received routine antibiotic therapy without any intraocular injection was remarkably similar (4.8% and 4.5%, respectively). The power of the study to detect this 0.3% difference was low, however this negligible difference is not clinically important.
In line with another report, 18 the presence of an IOFB was a confounder and significantly associated with the occurrence of endophthalmitis, but there was no significant difference between BSS injected eyes and noninjected eyes in rate of APBE after controlling for this independent risk factor.
We could not randomly allocate eyes to BSS injection versus non-injection because some patients had refused intraocular injection in the first place and were thus not enrolled in the TET study. However, baseline data and main factors such as age, sex, initial visual acuity, length and location of the laceration, lens injury, injury to repair interval, presence of IOFB, and vitreous prolapse were comparable between the study groups. The rate of additional procedures was significantly higher in non-injected eyes (64.9%) as compared to BSS injected eyes (35.9%). We are unable to explain this difference, but it further reinforces the notion that intraocular injections do not impose any additional risk.
The incidence of APBE has been reported to vary from 3.3% to 30% in different series depending on the setting of trauma. 20 Our initial report 18 disclosed a prominent protective role for intraocular antibiotics such that the rate of APBE in eyes harboring an IOFB but receiving prophylactic injections was nil. This is the lowest rate of endophthalmitis in the presence of IOFB in the literature.
One should not underestimate the risk of endophthalmitis following intraocular injection of any type. The cumulative per injection rate of endophthalmitis following intravitreal injection is 0.051%, which is slightly higher than a corresponding rate of 0.04% following incisional procedures such as cataract surgery. 10 This may be due to less strict adherence to aseptic technique during routine intraocular injections, which are becoming an office-based procedure. Pilli and colleagues demonstrated that the incidence of endophthalmitis was reduced by a factor of 4 when rules of surgical asepsis were respected. 21 To the best of our knowledge, the current study is the first to investigate the risk of endophthalmitis after intraocular injection in patients with PEI. The results of this study showed no significant difference between BSS injected and non-injected eyes in terms of development of APBE. Therefore one may conclude that the introduction of a needle for intraocular injection per se, entails no additional risk for APBE. These findings may further strengthen our previous observations regarding the reduced rate of APBE with prophylactic injection of intraocular antibiotics at the time of primary repair in PEIs, especially in the presence of an IOFB.
